The Walloon Region of Belgium has launched CIBLES, a Euro 25 million, five-year programme to validate new drug targets in the treatment of inflammation, cancer and central nervous system diseases.
The programme will be coordinated by the Université libre de Bruxelles, and will involve professors Marc Parmentier of the Institute for Interdisciplinary Research in Human and Molecular Biology and Etienne Pays of the Institute of Biology and Molecular Medicine, working in collaboration with teams from the Université Catholique de Louvain and the Université de Liège.
The research programme has also support of three industrial partners, Euroscreen, GlaxoSmithKline and UCB.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
